Comments on:

Affymetrix expects 1Q revenue below Street's view

Back to the article » |
SANTA CLARA, Calif. (AP) — The genetic testing instrument business Affymetrix Inc. expects first-quarter revenue below Wall Street expectations. The Santa Clara, Calif., company said Tuesday it expects total revenue of about $78 million for the quarter that ended March 31. That includes about $19 million from its eBioscience segment. Affymetrix will report full results April 30 after markets...

To learn more about commenting on and our community guidelines, please see our comments FAQ.